With 1.95 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.86 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.73 whereas the lowest price it dropped to was $6.3801. The 52-week range on TRVI shows that it touched its highest point at $7.39 and its lowest point at $2.30 during that stretch. It currently has a 1-year price target of $18.41. Beta for the stock currently stands at 0.37.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TRVI was up-trending over the past week, with a rise of 7.74%, but this was up by 63.09% over a month. Three-month performance surged to 162.65% while six-month performance rose 98.18%. The stock gained 120.20% in the past year, while it has gained 58.74% so far this year. A look at the trailing 12-month EPS for TRVI yields -0.44 with Next year EPS estimates of -0.53. For the next quarter, that number is -0.13. This implies an EPS growth rate of -74.92% for this year and -4.84% for next year.
Float and Shares Shorts:
At present, 75.45 million TRVI shares are outstanding with a float of 52.81 million shares on hand for trading. On 2025-02-28, short shares totaled 3.79 million, which was 424.0 higher than short shares on 1738281600. In addition to Ms. Jennifer L. Good as the firm’s Co-Founder, CEO, President & Director, Dr. Thomas R. Sciascia M.D. serves as its Co-Founder & Chief Scientific Officer.
Institutional Ownership:
Through their ownership of 0.90616995 of TRVI’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, TRVI reported revenue of $0.0 and operating income of -$14087000.0. The EBITDA in the recently reported quarter was -$13236000.0 and diluted EPS was -$0.13.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TRVI since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TRVI analysts setting a high price target of 29.0 and a low target of 11.0, the average target price over the next 12 months is 20.0625. Based on these targets, TRVI could surge 343.43% to reach the target high and rise by 68.2% to reach the target low. Reaching the average price target will result in a growth of 206.77% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.48657 being high and -$0.51762 being low. For TRVI, this leads to a yearly average estimate of -$0.50727. Based on analyst estimates, the high estimate for the next quarter is -$0.1 and the low estimate is -$0.15. The average estimate for the next quarter is thus -$0.13.
